Abnova Taiwan Corp - Asset Resilience Ratio
Abnova Taiwan Corp (4133) has an Asset Resilience Ratio of 0.07% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 4133 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2025)
This chart shows how Abnova Taiwan Corp's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Abnova Taiwan Corp.
Liquid Assets Composition Over Time
This chart breaks down Abnova Taiwan Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 4133 long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$886.00K | 0.07% |
| Total Liquid Assets | NT$886.00K | 0.07% |
Asset Resilience Insights
- Limited Liquidity: Abnova Taiwan Corp maintains only 0.07% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Abnova Taiwan Corp Industry Peers by Asset Resilience Ratio
Compare Abnova Taiwan Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Abnova Taiwan Corp (2008–2025)
The table below shows the annual Asset Resilience Ratio data for Abnova Taiwan Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.07% | NT$880.00K ≈ $27.72K |
NT$1.33 Billion ≈ $41.82 Million |
+0.00pp |
| 2022-12-31 | 0.06% | NT$849.00K ≈ $26.75K |
NT$1.37 Billion ≈ $43.31 Million |
+0.02pp |
| 2021-12-31 | 0.04% | NT$545.00K ≈ $17.17K |
NT$1.28 Billion ≈ $40.42 Million |
+0.00pp |
| 2020-12-31 | 0.04% | NT$543.00K ≈ $17.11K |
NT$1.29 Billion ≈ $40.79 Million |
0.00pp |
| 2019-12-31 | 0.04% | NT$540.00K ≈ $17.01K |
NT$1.26 Billion ≈ $39.82 Million |
+0.00pp |
| 2018-12-31 | 0.04% | NT$537.00K ≈ $16.92K |
NT$1.29 Billion ≈ $40.80 Million |
+0.00pp |
| 2017-12-31 | 0.04% | NT$533.00K ≈ $16.79K |
NT$1.30 Billion ≈ $41.08 Million |
-5.50pp |
| 2016-12-31 | 5.54% | NT$69.11 Million ≈ $2.18 Million |
NT$1.25 Billion ≈ $39.33 Million |
-10.15pp |
| 2015-12-31 | 15.69% | NT$195.97 Million ≈ $6.17 Million |
NT$1.25 Billion ≈ $39.35 Million |
+15.65pp |
| 2014-12-31 | 0.04% | NT$522.00K ≈ $16.45K |
NT$1.31 Billion ≈ $41.21 Million |
0.00pp |
| 2013-12-31 | 0.04% | NT$517.00K ≈ $16.29K |
NT$1.29 Billion ≈ $40.49 Million |
+0.00pp |
| 2012-12-31 | 0.04% | NT$513.00K ≈ $16.16K |
NT$1.29 Billion ≈ $40.71 Million |
+0.00pp |
| 2011-12-31 | 0.04% | NT$508.00K ≈ $16.00K |
NT$1.36 Billion ≈ $42.70 Million |
0.00pp |
| 2010-12-31 | 0.04% | NT$504.00K ≈ $15.88K |
NT$1.33 Billion ≈ $42.03 Million |
-1.09pp |
| 2009-12-31 | 1.13% | NT$14.72 Million ≈ $463.73K |
NT$1.31 Billion ≈ $41.13 Million |
-0.07pp |
| 2008-12-31 | 1.20% | NT$10.26 Million ≈ $323.21K |
NT$857.02 Million ≈ $27.00 Million |
-- |
About Abnova Taiwan Corp
Abnova (Taiwan) Corporation engages in the research, development, manufacturing, and sales of monoclonal and multiclonal antibodies, proteins, medical diagnostic instruments, and testing reagents. The company's products portfolio includes SARS-CoV/CoV-2, DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems,… Read more